Current treatment strategies in elderly patients with metastatic colorectal cancer

被引：9

作者：

Arkenau, Hendrik-Tobias ^{[1
]}

Chua, Yu Jo ^{[1
]}

Cunningham, David ^{[1
]}

机构：

[1] Royal Marsden Hosp London & Sutton, Dept Med Oncol, Sutton SM2 5PT, Surrey, England

来源：

CLINICAL COLORECTAL CANCER | 2007年 / 6卷 / 07期

关键词：

chemotherapy; 5-fluorouracil; irinotecan; leucovorin; oxaliplatin;

D O I：

10.3816/CCC.2007.n.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer (CRC) is one of the most common cancers in the Western world,with > 500,000 new cases diagnosed each year. One of the strongest risk factors for colon cancer is age. The incidence rates rise from 10 in 100,000 at age 40-45 years to 300 in 100,000 at age 75-80 years, with the median age at diagnosis of CRC being 71 years. With the general demographic shift toward an aging population, the number of people aged > 65 years is expected to increase. This article reviews the development of treatment for elderly patients with metastatic CRC, from single-agent fluoropyrimidines to combination therapies.

引用

页码：508 / 515

页数：8

共 55 条

[11] Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma - Final results of the southern Italy cooperative oncology group trial 0108 [J].

Comella, P ;

Natale, D ;

Farris, A ;

Gambardella, A ;

Maiorino, L ;

Massidda, B ;

Casaretti, R ;

Tafuto, S ;

Lorusso, V ;

Leo, S ;

Cannone, M .

CANCER, 2005, 104 (02) :282-289

[12] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[13]

D'Andre Stacy, 2005, Clin Colorectal Cancer, V4, P325, DOI 10.3816/CCC.2005.n.005

[14] First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients - A phase II study [J].

Daniele, B ;

Rosati, G ;

Tambaro, R ;

Ottaiano, A ;

De Maio, E ;

Pignata, S ;

Iaffaioli, RV ;

Rossi, A ;

Manzione, L ;

Gallo, C ;

Perrone, F .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 36 (03) :228-233

[15] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[16] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[17] ORAL DOXIFLURIDINE IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL-CANCER - A MULTICENTER PHASE-II STUDY [J].

FALCONE, A ;

PFANNER, E ;

RICCI, S ;

BERTUCCELLI, M ;

CIANCI, C ;

CARRAI, M ;

DEMARCO, S ;

CERIBELLI, A ;

BARDUAGNI, M ;

CALABRESI, F ;

COMELLA, G ;

SARCINA, R ;

LORUSSO, V ;

STAMPINO, CG ;

PANDOLFI, A ;

BRUZZI, P ;

CONTE, PF .

ANNALS OF ONCOLOGY, 1994, 5 (08) :760-762

[18]

Feliu J, 1997, CANCER-AM CANCER SOC, V79, P1884, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1884::AID-CNCR7>3.0.CO

[19]

2-G

[20] XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer [J].

Feliu, J ;

Salud, A ;

Escudero, P ;

Lopez-Gómez, L ;

Bolaños, M ;

Galán, A ;

Vicent, JM ;

Yubero, A ;

Losa, F ;

De Castro, J ;

de Mon, MA ;

Casado, E ;

González-Barón, M ;

Oncopaz Cooperative Grp .

BRITISH JOURNAL OF CANCER, 2006, 94 (07) :969-975

← 1 2 3 4 5 6 →